Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Bullboard Posts
Comment by Noloon Nov 20, 2019 5:17pm
175 Views
Post# 30375826

RE:20 test a day shouldn’t be hard to beat

RE:20 test a day shouldn’t be hard to beat
Choosesisely777 wrote: With only 20 test a day throughout all of the USA being performed now is basically nothing. We should exceed this with leaps and bounds in the coming quarters.


According to Tripp, the sales network in the US is pretty much setup with Telehealth, physicians and phlebotomy sites. But all this is pointless if they don't market the sh1t out of it. Marketing and advertising cost a lot of money. They'll have to spend heavily if they want to have revenue in return. 

And this is where those banks that approached Tripp could be useful. A few days ago, somebody here asked what would be the next NR about. I hope this is it: a deal with one of those banks. It is vital at this point given the cash we have on hand.  
Bullboard Posts